Sebastian Meltzer

Lorenskog, Norway

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 45 publications

Pooled analysis of 2 clinical trials of first-line chemoimmunotherapy for metastatic microsatellite stable colorectal cancer MEDITREME and METIMMOX studies.

Pooled analysis of 2 clinical trials of first-line chemoimmunotherapy for metastatic microsatellite stable colorectal cancer MEDITREME and METIMMOX studies.

Journal: Oncoimmunology

Published: June 20, 2026

Assessment of 16S rRNA sequencing for analysis of circulating microbial DNA in colorectal cancer patients-proof of concept and early changes during experimental chemoimmunotherapy.

Assessment of 16S rRNA sequencing for analysis of circulating microbial DNA in colorectal cancer patients-proof of concept and early changes during experimental chemoimmunotherapy.

Journal: Frontiers in microbiology

Published: February 02, 2026

MRI versus histopathology in EMVI detection for rectal cancer: prognostic relevance and survival outcomes.

MRI versus histopathology in EMVI detection for rectal cancer: prognostic relevance and survival outcomes.

Journal: European radiology

Published: January 31, 2026

Carcinoembryonic Antigen Flare Under Oxaliplatin-Based Chemotherapy Predicts Benefit from Nivolumab in Metastatic Microsatellite-Stable Colorectal Cancer - A Post Hoc Analysis of METIMMOX Trial Data.

Carcinoembryonic Antigen Flare Under Oxaliplatin-Based Chemotherapy Predicts Benefit from Nivolumab in Metastatic Microsatellite-Stable Colorectal Cancer - A Post Hoc Analysis of METIMMOX Trial Data.

Journal: ImmunoTargets and therapy

Published: January 09, 2026

Clinical outcomes of genomically guided trametinib monotherapy across cancer types: results from the IMPRESS-Norway trial.

Clinical outcomes of genomically guided trametinib monotherapy across cancer types: results from the IMPRESS-Norway trial.

Journal: Acta oncologica (Stockholm, Sweden)

Published: November 26, 2025

Subclinical cholestasis is a hallmark of gut dysbiosis causing resistance to cancer immunotherapy.

Subclinical cholestasis is a hallmark of gut dysbiosis causing resistance to cancer immunotherapy.

Journal: Cancer cell

Published: September 01, 2025

Exploratory biomarkers for oxaliplatin-induced nivolumab responsiveness in metastatic microsatellite-stable colorectal cancer.

Exploratory biomarkers for oxaliplatin-induced nivolumab responsiveness in metastatic microsatellite-stable colorectal cancer.

Journal: British journal of cancer

Published: August 13, 2025

Long-term disease-free survival in young-onset rectal cancer patients surgically treated with curative intent: a retrospective cohort study.

Long-term disease-free survival in young-onset rectal cancer patients surgically treated with curative intent: a retrospective cohort study.

Journal: International journal of colorectal disease

Published: June 09, 2025

Low b-values in apparent diffusion coefficient calculations overestimate diffusion in rectal cancer.

Low b-values in apparent diffusion coefficient calculations overestimate diffusion in rectal cancer.

Journal: Acta oncologica (Stockholm, Sweden)

Published: May 31, 2025

Dissemination of Mitochondrial DNA Variants: Looking at the 'Bigger' Picture of the Tumour Microenvironment in Rectal Cancer Patients.

Dissemination of Mitochondrial DNA Variants: Looking at the 'Bigger' Picture of the Tumour Microenvironment in Rectal Cancer Patients.

Journal: Journal of extracellular biology

Published: April 09, 2025

Low-intensity induction chemotherapy before chemoradiotherapy for rectal cancer: 10-year overall survival in the LARC-RRP trial.

Low-intensity induction chemotherapy before chemoradiotherapy for rectal cancer: 10-year overall survival in the LARC-RRP trial.

Journal: The British journal of radiology

Published: October 04, 2024

Complete response of metastatic microsatellite-stable BRAF V600E colorectal cancer to first-line oxaliplatin-based chemotherapy and immune checkpoint blockade.

Complete response of metastatic microsatellite-stable BRAF V600E colorectal cancer to first-line oxaliplatin-based chemotherapy and immune checkpoint blockade.

Journal: Oncoimmunology

Published: July 02, 2024

Showing 1-12 of 45

Last Updated: 09/26/2026